# Evaluate the Pharmacokinetics, Safety, and Tolerability of Nirsevimab in Healthy Chinese Adults

> **NCT04840849** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 24 (actual)

## Conditions studied

- Evaluate PK Profile

## Interventions

- **BIOLOGICAL:** nirsevimab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04840849
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-22
- **Primary completion:** 2021-11-18
- **Final completion:** 2021-11-18
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2023-11-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04840849

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04840849, "Evaluate the Pharmacokinetics, Safety, and Tolerability of Nirsevimab in Healthy Chinese Adults". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04840849. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*